申请人:Eli Lilly and Company
公开号:US20180215751A1
公开(公告)日:2018-08-02
The present invention provides a compound of Formula I:
or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treatment of neurodegenerative diseases and disorders, such as Alzheimer's disease.
本发明提供了I式化合物或其药学上可接受的盐,并且使用I式化合物治疗神经退行性疾病和障碍,如阿尔茨海默病。